Literature DB >> 23032895

Assessment of the risk for developing a second malignancy from scattered and secondary radiation in radiation therapy.

Harald Paganetti1.   

Abstract

With the average age of radiation therapy patients decreasing and the advent of more complex treatment options comes the concern that the incidences of radiation-induced cancer might increase in the future. The carcinogenic effects of radiation are not well understood for the entire dose range experienced in radiation therapy. Longer epidemiologic studies are needed to improve current risk models and reduce uncertainties of current risk model parameters. On the other hand, risk estimations are needed today to judge the risks versus benefits of modern radiation therapy techniques. This paper describes the current state-of-the-art in risk modeling for radiation-induced malignancies in radiation therapy, distinguishing between two volumes: first, the organs within the main radiation field receiving low or intermediate doses (typically between 0.1 and 50 Gy); and second, the organs far away from the treatment volume receiving low doses mainly due to scattered and secondary radiation (typically below 0.1 Gy). The dosimetry as well as the risk model formalisms are outlined. Furthermore, example calculations and results are presented for intensity-modulated photon therapy versus proton therapy.

Entities:  

Mesh:

Year:  2012        PMID: 23032895      PMCID: PMC3464436          DOI: 10.1097/HP.0b013e318261113d

Source DB:  PubMed          Journal:  Health Phys        ISSN: 0017-9078            Impact factor:   1.316


  84 in total

1.  On the conversion of solid cancer excess relative risk into lifetime attributable risk.

Authors:  A M Kellerer; E A Nekolla; L Walsh
Journal:  Radiat Environ Biophys       Date:  2001-12       Impact factor: 1.925

2.  Lung cancer after treatment for Hodgkin's disease: focus on radiation effects.

Authors:  E S Gilbert; M Stovall; M Gospodarowicz; F E Van Leeuwen; M Andersson; B Glimelius; T Joensuu; C F Lynch; R E Curtis; E Holowaty; H Storm; E Pukkala; M B van't Veer; J F Fraumeni; J D Boice; E A Clarke; L B Travis
Journal:  Radiat Res       Date:  2003-02       Impact factor: 2.841

3.  Relative biological effectiveness (RBE), quality factor (Q), and radiation weighting factor (w(R)). A report of the International Commission on Radiological Protection.

Authors: 
Journal:  Ann ICRP       Date:  2003

4.  Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time.

Authors:  A Foss Abrahamsen; A Andersen; O Nome; A B Jacobsen; H Holte; J Foss Abrahamsen; S Kvaløy
Journal:  Ann Oncol       Date:  2002-11       Impact factor: 32.976

5.  Secondary neutron dose during proton therapy using spot scanning.

Authors:  Uwe Schneider; Stefano Agosteo; Eros Pedroni; Jürgen Besserer
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-05-01       Impact factor: 7.038

6.  Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors.

Authors:  Raymond Miralbell; Antony Lomax; Laura Cella; Uwe Schneider
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-11-01       Impact factor: 7.038

7.  Relative biological effectiveness (RBE) values for proton beam therapy.

Authors:  Harald Paganetti; Andrzej Niemierko; Marek Ancukiewicz; Leo E Gerweck; Michael Goitein; Jay S Loeffler; Herman D Suit
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-06-01       Impact factor: 7.038

8.  Second primary tumors after radiotherapy for malignancies. Treatment-related parameters.

Authors:  Wolfgang Dörr; Thomas Herrmann
Journal:  Strahlenther Onkol       Date:  2002-07       Impact factor: 3.621

9.  Studies of mortality of atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality: 1950-1997.

Authors:  Dale L Preston; Yukiko Shimizu; Donald A Pierce; Akihiko Suyama; Kiyohiko Mabuchi
Journal:  Radiat Res       Date:  2003-10       Impact factor: 2.841

10.  Cancer risks attributable to low doses of ionizing radiation: assessing what we really know.

Authors:  David J Brenner; Richard Doll; Dudley T Goodhead; Eric J Hall; Charles E Land; John B Little; Jay H Lubin; Dale L Preston; R Julian Preston; Jerome S Puskin; Elaine Ron; Rainer K Sachs; Jonathan M Samet; Richard B Setlow; Marco Zaider
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-10       Impact factor: 11.205

View more
  11 in total

1.  Summary: achievements, critical issues, and thoughts on the future.

Authors:  Kathryn D Held
Journal:  Health Phys       Date:  2012-11       Impact factor: 1.316

Review 2.  Charged particle therapy--optimization, challenges and future directions.

Authors:  Jay S Loeffler; Marco Durante
Journal:  Nat Rev Clin Oncol       Date:  2013-05-21       Impact factor: 66.675

3.  Recommendations for the referral of patients for proton-beam therapy, an Alberta Health Services report: a model for Canada?

Authors:  S Patel; X Kostaras; M Parliament; I A Olivotto; R Nordal; K Aronyk; N Hagen
Journal:  Curr Oncol       Date:  2014-10       Impact factor: 3.677

Review 4.  Protons, Photons, and the Prostate - Is There Emerging Evidence in the Ongoing Discussion on Particle Therapy for the Treatment of Prostate Cancer?

Authors:  Kilian C Schiller; Gregor Habl; Stephanie E Combs
Journal:  Front Oncol       Date:  2016-01-28       Impact factor: 6.244

Review 5.  Pediatric Exposures to Ionizing Radiation: Carcinogenic Considerations.

Authors:  Kristy R Kutanzi; Annie Lumen; Igor Koturbash; Isabelle R Miousse
Journal:  Int J Environ Res Public Health       Date:  2016-10-28       Impact factor: 3.390

6.  Radiation-Induced Second Cancer Risk from External Beam Photon Radiotherapy for Head and Neck Cancer: Impact on in-Field and Out-of-Field Organs

Authors:  Vasanthan Sakthivel; Ganesh Kadirampatti Mani; Sunil Mani; Raghavendiran Boopathy
Journal:  Asian Pac J Cancer Prev       Date:  2017-07-27

7.  Estimating Second Malignancy Risk in Intensity-Modulated Radiotherapy and Volumetric-Modulated Arc Therapy using a Mechanistic Radiobiological Model in Radiotherapy for Carcinoma of Left Breast.

Authors:  Vasanthan Sakthivel; Ganesh Kadirampatti Mani; Sunil Mani; Raghavendiran Boopathy; Jothybasu Selvaraj
Journal:  J Med Phys       Date:  2017 Oct-Dec

8.  Propensity-score-matched evaluation of the incidence of radiation pneumonitis and secondary cancer risk for breast cancer patients treated with IMRT/VMAT.

Authors:  Pei-Ju Chao; Hsiao-Fei Lee; Jen-Hong Lan; Shih-Sian Guo; Hui-Min Ting; Yu-Jie Huang; Hui-Chun Chen; Tsair-Fwu Lee
Journal:  Sci Rep       Date:  2017-10-23       Impact factor: 4.379

9.  Plan Quality and Secondary Cancer Risk Assessment in Patients with Benign Intracranial Lesions after Radiosurgery using the CyberKnife M6 Robotic Radiosurgery System.

Authors:  Jen-Hong Lan; Chin-Shiuh Shieh; Chao-Hong Liu; I-Chun Cho; I-Hsing Tsai; Long-Chun Chen; Pei-Ju Chao; Hsiao-Fei Lee; Yu-Jie Huang; Tsair-Fwu Lee
Journal:  Sci Rep       Date:  2019-07-09       Impact factor: 4.379

10.  Influence of 68Ga-DOTATOC on sparing of normal tissue for radiation therapy of skull base meningioma: differential impact of photon and proton radiotherapy.

Authors:  Falk Stade; Jan-Oliver Dittmar; Oliver Jäkel; Clemens Kratochwil; Uwe Haberkorn; Jürgen Debus; Stephanie E Combs
Journal:  Radiat Oncol       Date:  2018-04-02       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.